Regorafenib beyond the Second Line in Relapsed Glioblastoma: A Case Report and Literature Review

Abstract

Glioblastoma multiforme (GBM) is one of the most frequent and aggressive primary tumors in the central nervous system, representing more than 60% of all brain tumors in adults. Primary GBM remains incurable with a poor prognosis both for limited therapeutic alternatives and for a high risk of progression or recurrence. In fact, at recurrence, the few treatment options available, and often characterized by limited effectiveness, have always been an Achilles’ heel. The recent approval of second line of regorafenib, a multikinase inhibitor, has given hope after several years of darkness for new therapies in the treatment of GBM. Indeed, in the REGOMA trial, a phase 2 study, regorafenib was the first drug to show a statistically significant improvement in median overall survival compared with lomustine group, usually used in the second-line treatment after temozolomide failure. We report a case of a 43-year-old patient affected by GBM in treatment with regorafenib in third line of therapy with good disease control and long PFS.

Overcoming multidrug resistance by reversan and exterminating glioblastoma and glioblastoma stem cells by delivering drug-loaded nanostructure hybrid lipid capsules (nHLCs)

“…For effective and lasting treatment, strategies should focus not only on overcoming MDR but eradicating MDR cancer as well. Recently, regorafenib (RF) has been approved by FDA for treatment of recurrent glioblastoma (REGOMA) [7]. Phase II trials of REGOMA with RF has shown better overall survival (OS) compared to other drugs in use [8].…”